Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan ...

"Novartis’ Cosentyx shows no benefit in Phase III GCA trial" was originally created and published by Clinical Trials Arena, a ...

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...

Hidradenitis suppurativa is a chronic, systemic, and often painful skin condition. Here’s what it’s like living with it.

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

Cosentyx treats certain forms of psoriasis and arthritis. Learn how to manage Conentyx's side effects, such as skin rash and headache.

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Please note Chef Michelle Bernstein is a COSENTYX® (secukinumab) patient and has been compensated for her time. Continue reading for Important Safety Information and a link to the full ...

Tremfya and Cosentyx for Psoriasis Treatment Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson’s (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in psoriasis ...

Please note NiYondashay is a COSENTYX ® (secukinumab) patient and has been compensated for her time. Continue reading for Important Safety Information and a link to the full Prescribing ...